Geranyl Acetate
CAS 105-87-3
Geranyl Acetate (CAS 105-87-3) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 29848.8 nM | 11 | - |
| - | IC50 | 73733.33333333333 nM | 3 | - |
| - | EC50 | 25800 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GERANYL ACETATE | 1807120 | SU | MTHSPL |
| geranyl acetate | 1807120 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Geranyl Acetate used for in pharmaceutical contexts?
Geranyl Acetate (CAS 105-87-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Geranyl Acetate?
No adverse-event association or SIDER side-effect rows are rendered for Geranyl Acetate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Geranyl Acetate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Geranyl Acetate with EU status "permitted".
What clinical phase is Geranyl Acetate in?
No phase 1-4 clinical development badge is rendered for Geranyl Acetate because the matched compound identifier rows do not contain a max-phase value.